Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2023, and other corporate highlights. “We had a very strong start to 2023 with record total revenue, strong underlying patient demand in all three commercial products, and the addition of.

Xeris Biopharma Reports First Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the C.

Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Xeris Biopharma Holdings (NASDAQ:XERS) said it has received a US patent covering formulations in its Gvoke product line used to treat severe hypoglycemia.  The patent issued by the US Patent and Trademark Office covers methods for using the formulations in treating hypoglycemia as well as manufacturing methods, the biopharma company said.

Xeris Biopharma secures US patent for XeriSol formulations

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the agreement, the company said it will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small-volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron.  Xeris will receive an upfront payment and potential milestone payments for preclinical achievements.

Xeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJect

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc.

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced the appointment of Ricki Fairley to its board of directors on March 27, 2023, increasing the size of the company's board to nine members. The growth-oriented biopharmaceutical firm said Fairley has over 35 years of marketing experience including 20 years in brand management at Johnson & Johnson (NYSE:JNJ), Nabisco, Reckitt & Colman, and The Coca-Cola Company (NYSE:KO).

Xeris Biopharma appoints brand management expert Ricki Fairley to its board of directors

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board to nine members, on March 27, 2023.

Xeris Biopharma Appoints Ricki Fairley to Board of Directors

Shares have lost over half their value during the past year. Commercial momentum appears to be building with management guiding for break-even cash flow by the end of 2023.

Xeris Biopharma: Picks And Shovels Play Has Long-Term Growth Potential

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Roanna Ruiz - SVB Securities David Amsellem - Piper Sandler Operator Hello and welcome to the Xeris Biopharma Fourth Quarter and Year-End 2022 Conference Call.

Xeris Biopharma Holdings, Inc. (XERS) Q4 2022 Earnings Call Transcript

Xeris Biopharma Holdings Inc (NASDAQ:XERS) posted record revenue growth for the fourth quarter and full-year 2022 and has issued bullish 2023 financial guidance. In the results statement, Paul R.

Xeris Biopharma posts record revenue growth for fourth quarter and full-year 2022

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year 2022 and provided 2023 financial guidance.

Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, March 8, 2023. Management will host a conference call and webcast at 8:30 a.m.

Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

Xeris Biopharma expects to report record net product revenue for 2022 thanks to strong growth across their portfolio of approved products. Xeris believes they are still on track to hit its goal of cash flow breakeven by the end of 2023.

Xeris Biopharma: Assessing The Growth And Valuation Disparity

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format.

Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

Xeris Biopharma Holdings (NASDAQ:XERS) Inc revealed that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals Inc, orphan-drug exclusivity (ODE) for Recorlev (levoketoconazole) for the treatment of adult patients with endogenous Cushing's syndrome, for whom surgery is not an option, or hasn't worked. Endogenous Cushing's syndrome is a rare and potentially fatal endocrine disease caused by chronic elevated cortisol exposure, which is often the result of a benign tumor of the pituitary gland.

Xeris Biopharma sees FDA grant Orphan-drug exclusivity to Recorlev for treatment of Cushing's syndrome

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals, Inc., orphan-drug exclusivity (ODE) for Recorlev® (levoketoconazole) for the treatment of adult patients with endogenous Cushing's syndrome for whom surgery is not an option or has not been curative.

Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 pm Pacific Time. To access the presentation, please visit “Events” on the investor relations page of the Company's website at www.xerispharma.com.

Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2022 expecting net product revenue to be at the top of its guidance range of $105 million to $110 million and its year-end cash balance to be above the previously announced range of $110 million to $120 million.

Xeris Biopharma Updates Its Outlook For 2022

Xeris Biopharma Holdings (NASDAQ:XERS) Inc announced that it will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism. The Chicago-based firm made the decision based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris told investors.

Xeris Biopharma to proceed with Phase II study of levothyroxine for hypothyroidism

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism. The Company anticipates initiating the study by the second half of 2023.

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

Horizon Pharma

Technology-based biopharma company Xeris (US:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Horizon Therapeutics (US:HZNP).

New Research Partnership With Horizon Therapeutics Could Be the Next Revenue Catalyst for Xeris

Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.

Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab

Xeris Biopharma Holdings (NASDAQ:XERS) said it has entered into a research collaboration and option agreement with Horizon Therapeutics PLC.  Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab and Horizon will have an option to license the Xeris technology.

Xeris Biopharma inks research collaboration and option agreement with Horizon Therapeutics

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP). Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect™, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab and Horizon will have an option to license the Xeris technology. Teprotumumab is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and potentially vision-threatening rare autoimmune disease. Teprotumumab-trbw is known as TEPEZZA® in the United States. Xeris will receive an upfront payment, and may be entitled to receive development milestones, regulatory milestones, and sales-based milestones, as well as royalties based on future sales if the commercial license option is exercised. Specific financial terms of the agreement were not disclosed.

News for Xeris Biopharma Holdings Stock (XERS)